Study summary
A weekly FcRn-blocking injection cut the risk of relapse by about 60%
61%lower risk of relapse than with placebo
What was tested
Efgartigimod PH20, a weekly under-the-skin injection that lowers harmful IgG antibodies by blocking the FcRn receptor, tested in people with active CIDP; responders were then randomized to keep taking it or switch to placebo.
What they found
- 66% (214 of 322) improved on open-label treatment.
- Among responders, relapse risk was 61% lower on efgartigimod than placebo (hazard ratio 0.39).
What it means
The first new type of CIDP treatment in decades and an alternative to regular immunoglobulin infusions.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.